STOCK TITAN
  1. Home
  2. News
  3. ICLR

Icon Plc - ICLR STOCK NEWS

Welcome to our dedicated page for Icon Plc news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.

ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.

Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.

ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.

This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.

Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.

News

ICON plc to Present at Upcoming Investor Conferences

Rhea-AI Summary
ICON plc (ICLR) CFO and CEO to present at upcoming healthcare conferences in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
-
News

ICON Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
ICON plc (NASDAQ:ICLR) reports strong financial results for the fourth quarter and full year 2023, with net business wins of $2,531 million in the quarter and $9,946 million for the full year. Revenue increased by 5.3% in quarter four to $2,066.2 million, with adjusted EBITDA of $448.2 million. Full-year revenue reached $8,120.2 million, with adjusted EBITDA of $1,694.1 million. GAAP net income for the quarter was $216.4 million, and $612.3 million for the full year. The company reaffirmed its financial guidance for 2024, expecting revenue of $8,400 - $8,800 million and adjusted earnings per share of $14.50 - $15.30.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
earnings
-
News

ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call

Rhea-AI Summary
ICON plc (ICLR) will release its Q4 and full year 2023 financial results on February 21, 2024, followed by a conference call and webcast on February 22, 2024. The company will discuss its performance and provide webcast links on its Investor section. A webcast replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
earnings
News

New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment

Rhea-AI Summary
ICON plc (ICLR) announced results from a survey of professionals engaged in obesity-related clinical research, revealing a focus on combination therapies and multi-indication studies. The majority of respondents believe future obesity therapies will focus on measuring more than one outcome. 66% of respondents are confident in their obesity-related pipeline success prospects. However, challenges include lack of long-term follow-up studies, obesity-specific trial design, and diverse patient recruitment. The survey highlights the potential for significant advancements in obesity clinical research in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
News

ICON Issues Financial Guidance for Full Year 2024

Rhea-AI Summary
ICON plc (ICLR) announces full year 2024 revenue guidance of $8,400 - $8,800 million, representing 3.2% – 8.1% growth over Full Year 2023. Adjusted earnings per share1 guidance is in the range of $14.50 - $15.30, representing growth of 13.5% – 19.8% over Full Year 2023. CEO Dr. Steve Cutler comments on the company's strengthened position as a market-leading provider of clinical development services and positive demand environment for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
News

Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON

Rhea-AI Summary
ICON plc (NASDAQ: ICLR) launches 'Optimising biotech funding' whitepaper to provide an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilize investment funding. A recent survey of over 130 biotech executives shows that 60% of respondents expected to increase R&D spending, while only 2% planned to reduce funding. The survey also highlights the challenges in bringing novel therapies to market and the need for biotechs to consider more comprehensive partnerships with clinical development partners. The whitepaper covers considerations for biotechnology companies pursuing funding from sources such as venture capital firms and partnerships with large pharmaceutical companies, strategic outsourcing decisions, and best practices to optimize trial designs, development timelines, and program value to maximize the impact of funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
clinical trial
News

ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
ICON plc (ICLR) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences
-
News

ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023

Rhea-AI Summary
ICON plc (NASDAQ: ICLR) is recognized as a top-rated employer and leader in clinical trial innovation, earning accolades for its ESG efforts, employee satisfaction, and diversity practices. The company ranked 88th in TIME’s list of the World’s Best Companies of 2023 and received recognition on Forbes' World’s Best Employers and World’s Top Companies for Women lists. Additionally, ICON was awarded the Financial Times Leaders in Diversity Award and the Frost & Sullivan Institute’s '2023 Enlightened Growth Leadership Award'. The company's CEO, Steve Cutler, emphasized ICON's commitment to achieving ESG goals and creating an inclusive workplace. Furthermore, ICON's digital innovation, marketing campaigns, and employee contributions were also acknowledged through various industry awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
News

ICON Secures Upgraded Credit Rating from Moody’s Investors Service

Rhea-AI Summary
ICON plc (ICLR) announced that Moody's Investors Service upgraded all of its instrument ratings to Baa3 with a stable outlook, reflecting a stronger credit profile and investment grade financial profile. The upgrade is attributed to ICON's good operating performance, conservative financial strategy, and risk management policies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
News

ICON plc to Present at Upcoming Investor Conferences

Rhea-AI Summary
ICON plc (NASDAQ: ICLR) CFO to present at Jefferies London Healthcare Conference and Evercore HealthCONx Conference, with webcasts available on the Investor section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences

FAQ

What is the current stock price of Icon Plc (ICLR)?

The current stock price of Icon Plc (ICLR) is $207.51 as of December 20, 2024.

What is the market cap of Icon Plc (ICLR)?

The market cap of Icon Plc (ICLR) is approximately 16.9B.

What services does ICON plc provide?

ICON plc provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries, including clinical trial management, laboratory, and imaging capabilities.

Where is ICON plc headquartered?

ICON plc is headquartered in Ireland.

What is ICON's role in pharmaceutical development?

ICON specializes in the strategic development, management, and analysis of clinical programs, supporting clinical development from compound selection to phase I-IV clinical studies.

Does ICON offer standalone and integrated services?

Yes, ICON provides both standalone and integrated full-service solutions to meet diverse client needs.

What is pharmacovigilance, and does ICON provide it?

Pharmacovigilance involves monitoring the effects of drugs after they have been licensed for use to ensure they are safe. ICON offers end-to-end pharmacovigilance services, including post-marketing surveillance.

What industries does ICON serve?

ICON serves the pharmaceutical, biotechnology, and medical device industries.

What makes ICON a leader in its industry?

ICON's capability to conduct clinical trials globally, strong financial health, strategic partnerships, and comprehensive service offerings make it a leader in the industry.

How can I stay updated on ICON's latest news and developments?

You can stay updated on ICON's latest news and developments by visiting reputable stock market websites or ICON's official website.

What are some of ICON's ancillary services?

ICON offers ancillary services, including laboratory and imaging capabilities, to support drug development and clinical research.

What type of clients does ICON work with?

ICON works with clients in the pharmaceutical, biotechnology, and medical device industries, providing them with comprehensive development and clinical trial services.

Stock ICLR logo
Icon Plc

Nasdaq:ICLR

ICLR Rankings

#608 Ranked by Market Cap
N/A Ranked by Dividends

ICLR Stock Data

16.93B
81.85M
0.66%
101.13%
1.55%
Diagnostics & Research
Healthcare
Link
United States of America
Dublin